Imugene Limited received approval from U.S. Patent and Trademark Office for PD1-Vaxx immunotherapy

Imugene Limited (ASX: IMU) announced that it had received approval from the U.S. Patent and Trademark Office for patent application number 16/498,929, associated with its B-cell activating immunotherapy PD1-Vaxx, which is presently in the development phase for non-small cell lung cancer. The patent titled “HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF” shields the company to 2038 the composition of matter and method of treatment in cancer of company’s PD1- Vaxx for the generation of a therapeutic antibody reaction against the programmed death-1 (PD1) checkpoint target.

The purpose of the phase 1b trial is to determine the safety, efficacy, and optimal dose of PD1-Vaxx in combination with atezolizumab as either first-line therapy in ICI treatment-naïve NSCLC patients or ICI pre-treated patients. The study will be directed at sites in USA and Australia.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com